ClinicalTrials.gg
Active, not recruitingNCT05633771HYRISSUpdated Nov 20, 2026

Observational Study, to Assess Treatment Retention of an Adalimumab Biosimilar (Hyrimoz®) in IBD Patients in Real Life Setting

An observational study in Inflammatory Bowel Disease, sponsored by Sandoz. Active, not recruiting at 51 sites in 2 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Sandoz (formerly part of Novartis) · Observational

How we know

Updated Nov 20, 2026Study completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
562
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 143 studies in Inflammatory Bowel Diseases with a site in France — 31 open to participants now, 42 under way, 7 of them phase 3. Inflammatory Bowel Diseases · France.

Planned enrollment
16th of 59
562 · median 220
Started
2023
with 6 others
Observational
59 of 143
15 open now
Primary completion
2025-12
later than 8 of 41 live
Registered
110th of 143
by date

Among the 143 studies in Inflammatory Bowel Diseases with a site in France, this one is the 16th largest by planned enrollment of the 59 observational ones that give a count, is one of 7 that started in 2023, is one of 59 observational ones, reaches primary completion later than 8 of the 41 other live ones, and was the 110th registered.

Inflammatory Bowel Diseases

1,555 studies on the registry are indexed under Inflammatory Bowel Diseases; 425 are open to participants now.

Browse Inflammatory Bowel Diseases studies →

Open to participants now

31 of the 143 studies in Inflammatory Bowel Diseases with a site in France are open now. Recruiting first, the newest first:

26 more — sign in →

All 31 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 276 Inflammatory Bowel Diseases studies recruiting now, 134 (49%) set no upper age limit and 114 (41%) stop at 75 or younger; 75 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 143 studies in Inflammatory Bowel Diseases with a site in France, or all of them as a file.
02

Study summary

An international, multicenter, non-interventional, prospective, post-authorization, descriptive, non-PASS, study.

Read the detailed description

The main purpose of this non-interventional study is to assess patient retention with Hyrimoz® treatment up to 6 months after treatment initiation in Inflammatory Bowel Disease (IBD) patients.

Primary data will be collected at each data collection time point (visits will be according to local clinical practice). Data will be collected based on the information reported in the medical records. This study does not impose a therapy protocol, procedure or change in routine medical practice. Apart from self-administered questionnaires, no additional examinations or assessments are required, consequently there are no additional medical risks for the patients. The total duration of the study will be 36 months (3 years). The recruitment period will be for 2 years with individual patient follow-up for up to 1 year.

It is expected that patients will visit their physicians at regular intervals depending on local specific clinical practices. Four time points for data collection will be defined:

  • T0 (patient inclusion in the study and Baseline characteristics).
  • T1 (3-month follow-up ± 1 month).
  • T2 (6-month follow-up and primary criteria -2/+3 months).
  • T3 (12-month follow-up -3/+2 months).
03

Conditions studied

  • Inflammatory Bowel Disease

Keywords

  • Inflammatory Bowel Disease
  • IBD
  • NIS
  • HYRISS
  • adalimumab
  • Hyrimoz
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients for whom the investigator has decided to initiate treatment with Hyrimoz® in accordance with the approved SmPC and local clinical practice, will be eligible to participate in the study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients must meet all of the following criteria at Baseline:

  • Patients initiating Hyrimoz® treatment.
  • Patients with a confirmed diagnosis (following local recommendations) of one of these indications: CD or UC.
  • Patients ≥ 18 years of age.
  • Patient in whom the decision to initiate Hyrimoz® (naïve population) or to switch (switch population) from reference adalimumab to Hyrimoz® was accorded with his physician before the proposal to participate in the study.
  • Patients meeting one of the following criteria:

    • Referred to as "switched patients": Patients treated continuously with adalimumab (other than Hyrimoz®) for at least 6 months, with an indication for continuing treatment with adalimumab at any therapeutic dose (physician's decision) and who have controlled stable disease for at least 3 months before study enrollment (according to the physician's criteria).
    • Referred to as "biologic-naive patients": Patients who had an inadequate response or to conventional therapy with no exposure to any biological medicine and targeted therapies and started Hyrimoz® as a biologic therapy according to the summary of product characteristics (SmPC).
  • Patients able to complete and understand the self-administered questionnaires.
  • Patients who have been informed and have provided a signed written consent as per local regulations prior to participation in the study

Exclusion criteria

Exclusion Criteria:

Patients fulfilling any of the following criteria are not eligible for inclusion in this study:

  • Patients enrolled in an ongoing interventional study.
  • Patients with any to Hyrimoz® according to the SmPC.
  • Patients at imminent risk of scheduled intestinal surgery (stenosis, strictures, internal fistula).
  • Use of any drug in last 6 months prior to enrollment.
  • Patient received any biological medicine or targeted therapy, in case of " biologic-naive patient ",
  • Patient received adalimumab for less than 6 months or have controlled disease for less than 3 months, in case of "switched patient".
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
562 participants (estimated)
Patient registry
No

Groups and cohorts

  • Hyrimoz

    Patients prescribed with Hyrimoz

    Other: Hyrimoz

Interventions

  • OtherHyrimoz

    There is no treatment allocation. Patients administered Hyrimoz by prescription that have started as routine medical treatment will be enrolled.

    Also known as: adalimumab biosimilar

06

What researchers measure

Primary outcomes

  1. Percentage of patients who remain on Hyrimoz® at 6 months after treatment initiation

    Assess patient retention with Hyrimoz® treatment up to 6 months after treatment initiation

    Time frame: Up to 6 months

Secondary outcomes

  1. Percentage of patients who discontinue Hyrimoz

    Percentage of patients who discontinue Hyrimoz® at T2 and T3 due to: * Lack of efficacy. * Intolerance/Adverse event(s) or special scenario. * Patient's decision * Nocebo effect * Other reasons.

    Time frame: 6 months, 12 months

  2. Percentage of patients with high level of treatment satisfaction using TSQM-9 questionnaire

    To assess patients' treatment satisfaction (based on 9-item Treatment Satisfaction Questionnaire for Medication \[TSQM 9\], the percentage of patients with high level of treatment satisfaction (score ≥ 39) will be collected. The TSQM-9 is declined with 9 questions about patient treatment satisfaction. Each answer gives a number of points depending of the question and the answer. The final score is the sum of points in each question. This questionnaire score from 9 to 59 points. In HYRISS study, we estimate that patient with \< 39 pts in TSQM-9 are considered with a low satisfaction for the medication (satisfaction under 60%).

    Time frame: 3 months, 6 months, 12 months

  3. Percentage of patients with high level of treatment adherence using adapted CQR5 questionnaire

    To assess adherence/compliance to treatment (based on 5 item Compliance Questionnaire for Rheumatology \[CQR5\] adapted for gastroenterologist), percentage of patients with high level of treatment adherence (score ≥ 15) using adapted CQR5 questionnaire will be collected. The CQR5 is declined with 5 questions about patient compliance to the treatment. Each answer gives from 1 to 4 points depending of the answer. The final score is the sum of points in each question. This questionnaire score from 5 (very low compliance) to 20 points (very strong compliance).

    Time frame: Baseline, 3 months, 6 months, 12 months

  4. Percentage of patients with the perception of a high level of disease activity using VAS scale

    To assess the patient's reported disease activity, percentage of patients with the perception of a high level (score ≥ 6) of disease activity will be collected using visual analog scale \[VAS\]. This visual analogue scale (VAS) is an instrument designed to document the disease activity. Patients are asked to rate their disease activity on a visual analogue scale (VAS): How active has your disease been this week? From 0 (Not active at all) to 10 cm (Extremely active).

    Time frame: Baseline, 3 months, 6 months, 12 months

  5. Percentage of patients with a good perception about biosimilars using VAS scale

    To assess the patient's reported perception about biosimilars at the inclusion visit, percentage of patients with a good perception (score ≥ 6) about biosimilars using VAS scale will be measured. This visual analogue scale (VAS) is an instrument designed to document the perception of the patient about biosimilar. Patients are asked to rate their perception of biosimilar medicine on a visual analogue scale (VAS): Are you confident in using biosimilar? From 0 (I have no confidence at all) to 10 cm (I have a great confidence).

    Time frame: Baseline

  6. Percentage of patients in remission

    Remission defined as Harvey-Bradshaw Index \[HBI\] ≤ 4 \[for Crohn's Disease\] or partial Mayo score ≤ 1 \[for Ulcerative Colitis\]

    Time frame: Baseline, 3 months, 6 months, 12 months

  7. Crohn's disease activity measurement: Harvey Bradshaw Index [HBI]

    Crohn's disease activity will be measured with HBI score. Score is interpreted: \<4: Remission 4-7: Mild disease 8-16: Moderate disease \>16: Severe disease

    Time frame: Up to 12 months

  8. Ulcerative colitis activity measurement: partial Mayo calculation score

    Ulcerative colitis activity will be measured using partial Mayo calculation score. Score is interpreted: ≤ 1: Remission 2 - 4: Low activity disease 5 -6: Moderate disease 7 - 9: Severe disease

    Time frame: Up to 12 months

  9. Pattern of Hyrimoz® utilization

    Pattern of Hyrimoz® utilization to be collected

    Time frame: Up to 12 months

07

Study locations

51 sites
  • Sandoz Investigational Site Belgium
    Aalst, Belgium
  • Sandoz Investigational Site Belgium
    Antwerp, Belgium
  • Sandoz Investigational Site Belgium
    Bonheiden, Belgium
  • Sandoz Investigational Site Belgium
    Brussels, Belgium
  • Sandoz Investigational Site Belgium
    Eeklo, Belgium
  • Sandoz Investigational Site Belgium
    Ghent, Belgium
  • Sandoz Investigational Site Belgium
    Herentals, Belgium
  • Sandoz Investigational Site Belgium
    Kortrijk, Belgium
  • Sandoz Investigational Site Belgium
    Liège, Belgium
  • Sandoz Investigational Site Belgium
    Namur, Belgium
  • Sandoz Investigational Site Belgium
    Seraing, Belgium
  • Sandoz Investigational Site Belgium
    Sint-Niklaas, Belgium
  • Sandoz Investigational Site Belgium
    Tongeren, Belgium
  • Sandoz Investigational Site France
    Amiens, France
  • Sandoz Investigational Site France
    Auxerre, France
  • Sandoz Investigational Site France
    Bayonne, France
  • Sandoz Investigational Site France
    Beauvais, France
  • Sandoz Investigational Site France
    Brest, France
  • Sandoz Investigational Site France
    Caen, France
  • Sandoz Investigational Site France
    Castelnau-le-Lez, France
  • Sandoz Investigational Site France
    Clermont-Ferrand, France
  • Sandoz Investigational Site France
    Clichy, France
  • Sandoz Investigational Site France
    Cornebarrieu, France
  • Sandoz Investigational Site France
    Créteil, France
  • Sandoz Investigational Site France
    Gien, France
  • Sandoz Investigational Site France
    Le Coudray, France
  • Sandoz Investigational Site France
    Le Kremlin-Bicêtre, France
  • Sandoz Investigational Site France
    Lille, France
  • Sandoz Investigational Site France
    Lyon, France
  • Sandoz Investigational Site France
    Marseille, France
  • Sandoz Investigational Site France
    Montpellier, France
  • Sandoz Investigational Site France
    Nancy, France
  • Sandoz Investigational Site France
    Neuilly-sur-Seine, France
  • Sandoz Investigational Site France
    Nice, France
  • Sandoz Investigational Site France
    Nîmes, France
  • Sandoz Investigational Site France
    Orléans, France
  • Sandoz Investigational Site France
    Paris, France
  • Sandoz Investigational Site France
    Pessac, France
  • Sandoz Investigational Site France
    Pierre-Bénite, France
  • Sandoz Investigational Site France
    Poitiers, France
  • Sandoz Investigational Site France
    Pringy, France
  • Sandoz Investigational Site France
    Reims, France
  • Sandoz Investigational Site France
    Rennes, France
  • Sandoz Investigational Site France
    Saint-Etienne, France
  • Sandoz Investigational Site France
    Saint-Nazaire, France
  • Sandoz Investigational Site France
    Sarrebourg, France
  • Sandoz Investigational Site France
    Toulouse, France
  • Sandoz Investigational Site France
    Tours, France
  • Sandoz Investigational Site France
    Troyes, France
  • Sandoz Investigational Site France
    Vandœuvre-lès-Nancy, France
  • Sandoz Investigational Site France
    Vénissieux, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2023 to primary completion in Dec 2025, 33 months.

Of 37 industry-sponsored observational studies under Inflammatory Bowel Diseases, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 44. This study's 33 months is close to that.

Counting every sponsor, half of 281 studies reached it within 36 months; a quarter within 20 and three quarters within 122.

Completion moved once since we started tracking on Sep 25, 2026: Dec 2026 → Mar 2027, on Nov 20, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2022
First posted
Dec 1, 2022
StartActual
Feb 16, 2023
Primary completionActual
Dec 15, 2025
CompletionEst.
Mar 2027was Dec 2026
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Study completion
Dec 2026→Mar 2027
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Study completion Dec 2026→Mar 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05633771
Lead sponsor
Sandoz
Responsible party
Sponsor
First posted
Dec 1, 2022
Start date
Feb 16, 2023
Primary completion
Dec 15, 2025
Completion
Mar 2027 (estimated)
Last update
Nov 20, 2026
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion